Akebia Therapeutics, Inc. AKBA

Healthcare — Drug Manufacturers Specialty & Generic

0.90 (0.02) (2.17%) as of 25 Sep

Market cap: $254.7M
P/E: 0.0×

Follow AKBA

Insider Buys (last 12m)

Insider Buys alert about insiders buying in the last 12 month

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16
Revenue	236.20	160.18	194.62	292.48	211.65	294.64	335.00	207.74	181.23	1.54
Revenue Growth	47.46%	(17.70%)	(33.46%)	38.19%	(28.17%)	(12.05%)	61.26%	14.63%	11,706.32%	(99.15%)
Cost of Revenue	39.46	63.18	74.15	85.57	150.67	182.05	145.34	7.77	0.62	—
Gross Profit	196.73	97.00	120.47	206.92	60.98	112.59	189.67	199.97	181.23	1.54
R&D Expenses	62.36	37.65	63.08	129.99	147.85	218.49	322.97	291.01	230.89	115.79
SG&A Expenses	107.48	106.55	100.23	138.60	174.14	154.10	149.46	87.06	27.01	22.21
Operating Income	23.50	(50.47)	(46.26)	(80.78)	(264.50)	(377.83)	(286.29)	(178.16)	(76.67)	(136.46)
Non-operating Income/Expense	(27.22)	(18.94)	(5.67)	(13.45)	(17.52)	(7.01)	0.00	6.24	3.00	0.71
Non-operating Interest Expenses	24.18	18.19	6.03	15.69	19.94	8.87	(0.79)	6.15	2.80	0.90
EBT	(3.72)	(69.41)	(51.92)	(94.23)	(282.02)	(384.84)	(286.29)	(171.93)	(73.67)	(135.75)
Income Tax Provision	1.62	—	—	—	—	—	(6.63)	(28.34)	—	—
Income after Tax	(5.34)	(69.41)	(51.92)	(94.23)	(282.02)	(384.84)	(279.66)	(143.59)	(73.67)	(135.75)
Net Income Common	(5.34)	(69.41)	(51.92)	(94.23)	(282.02)	(384.84)	(279.66)	(143.59)	(73.67)	(135.75)
EPS (Basic)	(0.02)	(0.33)	(0.28)	(0.51)	(1.70)	(2.77)	(2.36)	(2.47)	(1.77)	(3.60)
EPS (Diluted)	(0.02)	(0.33)	(0.28)	(0.51)	(1.70)	(2.77)	(2.36)	(2.47)	(1.77)	(3.60)
Shares (Basic, Weighted)	257.16	210.95	187.47	182.78	165.95	138.46	118.40	58.04	43.50	37.72
Shares (Diluted, Weighted)	257.16	210.95	187.47	182.78	165.95	138.46	118.40	58.04	43.50	37.72
Gross Margin	83.29%	60.56%	61.90%	70.74%	28.81%	38.21%	56.62%	96.26%	100.00%	100.00%
EBIT Margin	9.95%	(31.51%)	(23.77%)	(27.62%)	(124.97%)	(128.23%)	(85.46%)	(85.76%)	(42.31%)	(8,889.90%)
EBT margin	(1.58%)	(43.33%)	(26.68%)	(32.22%)	(133.25%)	(130.61%)	(85.46%)	(82.76%)	(40.65%)	(8,843.45%)
Net Profit Margin	(2.26%)	(43.33%)	(26.68%)	(32.22%)	(133.25%)	(130.61%)	(83.48%)	(69.12%)	(40.65%)	(8,843.45%)
Free Cash Flow Margin	28.74%	(25.40%)	(12.02%)	(25.05%)	(119.55%)	(37.57%)	(78.83%)	(47.70%)	(31.88%)	3,598.96%
EBITDA	24.77	(12.97)	(8.63)	(43.08)	(226.55)	(228.76)	(248.46)	(176.97)	(75.45)	(135.67)
EBIT	23.50	(50.47)	(46.26)	(80.78)	(264.50)	(377.83)	(286.29)	(178.16)	(76.67)	(136.46)
Income from Continuous Operations	(5.34)	(69.41)	(51.92)	(94.23)	(282.02)	(384.84)	(279.66)	(143.59)	(73.67)	(135.75)
Consolidated Net Income/Loss	(5.34)	(69.41)	(51.92)	(94.23)	(282.02)	(384.84)	(279.66)	(143.59)	(73.67)	(135.75)
EPS (Basic, from Continuous Ops)	(0.02)	(0.33)	(0.28)	(0.52)	(1.70)	(2.78)	(2.36)	(2.47)	(1.69)	(3.60)
EPS (Basic, Consolidated)	(0.02)	(0.33)	(0.28)	(0.52)	(1.70)	(2.78)	(2.36)	(2.47)	(1.69)	(3.60)
EPS (Diluted, from Cont. Ops)	(0.02)	(0.33)	(0.28)	(0.52)	(1.70)	(2.78)	(2.36)	(2.47)	(1.69)	(3.60)
Shares (Diluted, Average)	257.16	210.95	187.47	182.78	165.95	138.46	118.40	58.04	43.50	37.72
EPS (Diluted, Consolidated)	(0.02)	(0.33)	(0.28)	(0.52)	(1.70)	(2.78)	(2.36)	(2.47)	(1.69)	(3.60)
EBITDA Margin	10.49%	(8.10%)	(4.43%)	(14.73%)	(107.04%)	(77.64%)	(74.17%)	(85.19%)	(41.63%)	(8,838.44%)
Operating Cash Flow Margin	28.79%	(25.38%)	(12.02%)	(25.01%)	(119.52%)	(37.46%)	(76.85%)	(46.93%)	(30.99%)	3,772.38%

Show all line items

In millions of $ except per-share values · columns are period end dates

Powerpack

Full quarterly history

Analyst estimates

Unlimited screener

Unlimited Excel

Unlimited follows

Akebia Therapeutics, Inc. AKBA